Green Propellants: Fast-Tracking Healthier Tomorrows For Patients And Our Planet

Reducing the environmental impact of inhaled therapies has become a priority as global regulations increasingly target high‑GWP propellants. This resource explores how next‑generation low‑GWP options can maintain the performance expectations of current inhaler platforms while significantly lowering their climate footprint. With decades of respiratory development experience — including the invention of the first pMDI and leadership during the transition to CFC‑free technology — this content demonstrates how established expertise can accelerate the shift toward more sustainable systems without compromising quality or development timelines.

It also outlines strategic considerations for adopting new propellant technologies, including regulatory readiness, formulation compatibility, device integration, and planning for clinical and commercial scale. Flexible hardware components and proven drug‑device engineering approaches help teams navigate the transition efficiently, ensuring upcoming products meet both performance expectations and evolving environmental requirements.

For organizations preparing their long‑term respiratory portfolio, this preview highlights the practical steps required to stay ahead of regulatory change and build a more sustainable inhalation pipeline. Explore the full asset to understand better how low‑GWP propellants can support future product strategies.